|
Workshop
Antibody Drug Conjugates: Chemistry, Biology, Pharmacokinetics and Toxicology
Speakers:
Jagath Junutula (Cellerant), Andy Polson (Genentech) , Toni Kline (Sutro), Chetana Rao (BMS), Donglu Zhang (Genentech), Keyang Xu, PhD (Genentech), Melissa Schutten (Genentech)
Organizers:
Thomas Pillow (Genentech)
Date:
2018-09-12
Time:
8:45-16:00 Pacific Time
Registration fee:
(USD): Regular: $195; For unemployed or students: $30; Academic: $125; For major-sponsor rep (incl lunch): $0; For vendor-show rep: $35
Location:
SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date:
(24)AIT Bioscience; Alturas Analytics; Applied StemCell, Inc.; Averica Discovery Services; BioPharmEquip; Bruker; Bruker; Celerion; JOINN Labs; KCAS Bio; MabPlex; Medpace; MicroConstants; Pacific BioLabs; PHARMout Laboratories; Promega; QPS; SCIEX; Sekisui XenoTech, LLC; Selvita Inc.; Sepax Technologies; Sigma Aldrich; SRI International; WuXi AppTec
Registration: http://www.PBSS.org
Registration deadline:2018-09-11
(it will close sooner if the seating cap is reached)
About the Topic
Linking a small-molecule cytotoxic drug to a monoclonal antibody takes the strengths of both while potentially mitigating the liabilities. The resulting bioconjugates, known as antibody−drug conjugates or ADCs, have been validated clinically, with four approved anti-cancer agents for solid and hematological cancers. This workshop will broadly discuss the strategies for designing, constructing and analyzing ADCs utilizing the latest advances in the field.
This workshop will cover the following specific topics:
- Overview of antibody-drug conjugates (ADCs) and clinical progress
- Selecting a target for ADCs
- The chemistry of linkers and drugs
- Site-specific conjugation
- Analytical characterization of ADCs
- ADC bioanalysis & pharmacokinetics
- Preclinical safety/toxicology
Workshop Agenda:
Time |
Topic |
Presenter |
8:45-9:00 |
Welcome and Introduction |
Thomas Pillow |
9:00-9:45 |
1. ADC Discovery & Development |
Jagath Junutula |
9:45-10:30 |
2. ADCs for Hematological Malignancies |
Andy Polson |
10:30-10:45 |
Break |
|
10:45-11:30 |
3. Conjugation Modalities for ADC Generation |
Chetana Rao |
11:30-12:30 |
Lunch |
|
12:30-1:15 |
4. ADC Chemistry |
Toni Kline |
1:15-2:00 |
5. Small Molecule DMPK for ADCs |
Donglu Zhang |
2:00-2:15 |
Break |
|
2:15-3:00 |
6. Bioanalysis of ADCs |
Keyang Xu |
3:00-3:45 |
7. ADC Safety/Toxicity |
Melissa Schutten |
3:45-4:15 |
Panel Discussion |
All |
4:15-4:30 |
Final Remarks |
Thomas Pillow |
2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
|
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Online Workshop] Career Transition for Research Scientists
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Submit a Text Ad
|